California-based OncoMed Pharmaceuticals, a developer focused on antibody therapeutics that target cancer stem cells, announced the appointment of Sunil Patel to SVP, corporate development. Patel will be responsible for corporate business development, and will report to Paul Hastings, president and CEO. Patel was previously VP, corporate development and marketing at BiPar Sciences, which was acquired by Sanofi-Aventis last April.
DOR BioPharma, a late-stage biopharmaceutical company based in New Jersey, tapped Christopher Schnittker as vice president of administration and controller. Schnittker will oversee accounting, human resources and other administrative functions.